









Markets
/
Stocks
/
nasdaq-sxtc
/

China SXT Pharmaceuticals Inc

SXTC

1.660USD

+0.240+16.90%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

22.85MMarket Cap

--P/E TTM



China SXT Pharmaceuticals Inc

1.660

+0.240+16.90%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of China SXT Pharmaceuticals Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is low. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

China SXT Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

142 / 173

Overall Ranking

626 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

China SXT Pharmaceuticals Inc Highlights

StrengthsRisks

China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The Company develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The Company sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.74M.

Fairly Valued

The company’s latest PE is -0.54, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 166.43K shares, increasing 47.80% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77. Its latest quarterly revenue reached 829.49K, representing a year-over-year decrease of 11.72%, while its net profit experienced a year-over-year decrease of 91.72%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

China SXT Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.28, which is lower than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -0.54, which is -58.00% below the recent high of -0.23 and -127.01% above the recent low of -1.23.

Score

Industry at a Glance

Previous score

6.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 2.31, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 1.67 and the support level at 1.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.10

Change

0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.063

Neutral

RSI(14)

63.343

Neutral

STOCH(KDJ)(9,3,3)

74.009

Neutral

ATR(14)

0.133

High Vlolatility

CCI(14)

351.942

Overbought

Williams %R

22.034

Buy

TRIX(12,20)

-0.649

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.454

Buy

MA10

1.390

Buy

MA20

1.410

Buy

MA50

1.557

Buy

MA100

1.611

Buy

MA200

2.123

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Foong Soon Hong (Randy)

10.59M

Seng (Tan Soo)

10.39M

Tan (Cheng Guan)

10.20M

Ching (Choon Hwa)

9.80M

Invesco Capital Management LLC

Star Investors

89.66K

UBS Financial Services, Inc.

62.60K

+1087.84%

Virtu Americas LLC

13.97K

Forsakringsaktiebolaget Skadinviska Enskilda

5.63K

+46.68%

Zhou (Feng)

532.00

-94.18%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 1.47. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.